Skip to main content
  • Saved

made a Post

Potential T2DM drug HMPA promotes short-chain fatty acid production by improving carbon catabolite repression effect of gut microbiota. - ClinOwl

Potential T2DM drug HMPA promotes short-chain fatty acid production by improving carbon catabolite repression effect of gut microbiota. - ClinOwl

Source :

https://clinowl.com/potential-t2dm-drug-hmpa-promotes-short-chain-fatty-acid-production-by-improving-carbon-catabolite-repression-effect-of-gut-microbiota/

Gut microbiota plays an important role in type 2 diabetes mellitus (T2DM) progression. HMPA (N-(4-hydroxyphenethyl)-3-mercapto-2-methylpropanamide) is a potential T2DM drug screened out in our previous work. This work evaluated the effect of HMPA on gut microbiota and studied the molecular mechanism underlying HMPA's regulation of gut microbiota.The pseudo germ-free (PGF) T2DM model and fecal microbiota transplantation method were used to study whether gut microbiota mediates the pharmacological action of HMPA.